Chronic Lymphocytic Leukemia News and Research

RSS

Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.

Research unveils bispecific antibodies for B-cell lymphoma treatment

A new research paper was published in Oncotarget's Volume 15 on April 12, 2024, entitled, "Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface."

16 Apr 2024

Study evaluates the feasibility of discontinuing CLL specialist care

A study published today in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, fewer infections, and similar survival after three years compared to those who continued to undergo specialized follow-up.

4 Apr 2024

New Blood Cancer Healing Center poised to redefine care standards

The Blood Cancer Healing Center, located at 3229 Burnet Avenue in Uptown Cincinnati, is poised to redefine care standards by offering comprehensive patient support and innovative treatments under one roof.

15 Feb 2024

Combination treatments reduce blood pressure in patients taking ibrutinib

Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances.

5 Feb 2024

Next-gen BTK degrader could help overcome treatment resistance in chronic lymphocytic leukemia

New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia (CLL) and related blood cancers.

1 Feb 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

Personalized treatment for leukemia results in longer life and fewer side effects

Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found.

11 Dec 2023

Targeted drug may offer a new treatment option for patients with relapsed blood cancer

A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments.

6 Nov 2023

As covid infections rise, nursing homes are still waiting for vaccines

"Covid is not pretty in a nursing home," said Deb Wityk, a 70-year-old retired massage therapist who lives in one called Spurgeon Manor, in rural Iowa. She twice contracted the disease and is eager to get the newly approved vaccine because she has chronic lymphocytic leukemia, which weakens her immune system.

27 Sep 2023

Annual NCCN Congress to focus on latest advances in blood cancer treatment

The National Comprehensive Cancer Network 2023 Annual Congress: Hematologic Malignancies returns to San Francisco this week, for the first time since 2019.

19 Sep 2023

NCCN publishes new resource on options, benefits of care approaches for pediatric Hodgkin lymphoma

The National Comprehensive Cancer Network today announced the publication of NCCN Guidelines for Patients®: Hodgkin Lymphoma in Children.

22 Aug 2023

Research reveals therapeutic potential of novel compound in inhibiting oncogene translation

Cutting-edge research at the Luxembourg Institute of Health reveals the ground-breaking therapeutic potential of the compound FL3 in inhibiting oncogene translation and rewiring cancer cell metabolism, opening up new therapeutic opportunities for leukemia patients.

24 Jul 2023

Patients with high-risk chronic lymphocytic leukemia may benefit from treatment with ibrutinib plus venetoclax

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk genetic features typically associated with poor outcomes, according to results published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR).

7 Jun 2023

Fred Hutch experts highlight research on cancer treatment advances, survivorship and precision oncology at ASCO

At the 2023 American Society for Clinical Oncology Annual Meeting—to be held June 2-6 in Chicago, Illinois—Fred Hutchinson Cancer Center experts will present research spanning survivorship, advances in treatments and clinical trials, how access to cancer care affects outcomes, integrative medicine and more.

5 Jun 2023

Ultra-processed food and cancer: is there a link?

Researchers performed a meta-analysis to evaluate the relationship between ultra-processed food and cancer.

5 Apr 2023

Three-drug combination highly effective in patients with high-risk forms of chronic lymphocytic leukemia

A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

12 Dec 2022

Ongoing Phase I clinical trial demonstrates successful re-treatment with CAR T cell therapy

Researchers from the University of Pennsylvania's Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology Annual Meeting.

12 Dec 2022

Whole-genome sequencing reveals five new subgroups of chronic lymphocytic leukemia

A collaborative study led by the University of Oxford as part of the UK's 100,000 Genomes Project, published in Nature Genetics today, has defined five new subgroups of the most common type of blood cancer, chronic lymphocytic leukemia (CLL) and associated these with clinical outcomes.

16 Nov 2022

Better physical fitness reduces frailty risk in patients with chronic lymphocytic leukemia

Increased levels of exercise could help reduce frailty in patients with the most common form of leukemia, chronic lymphocytic (CLL), according to new research from the University of Surrey.

21 Sep 2022

How and when do de novo SARS-CoV-2 spike mutations emerge?

Researchers evaluated viral mutations in two patients with persistent SARS-CoV-2 infection.

1 Aug 2022